Pharmaceutics (Nov 2022)

Self−Assembling Anchorage of Hyaluronic Acid on the Nanoparticle Surface Confers Superiority of Triple Negative Breast Cancer Treatment

  • Yingpeng Li,
  • Liang Liu,
  • Hongtao Shang,
  • Xuchen Feng,
  • Ni Fan,
  • Jingyu Wang,
  • Yuqi Wu,
  • Yatong Chen,
  • Xinhong Chu,
  • Min Zhong,
  • Yujiao Sun,
  • Hui Fu,
  • Wei Huang,
  • Yunfei Li

DOI
https://doi.org/10.3390/pharmaceutics14112461
Journal volume & issue
Vol. 14, no. 11
p. 2461

Abstract

Read online

Triple-negative breast cancer (TNBC) has been listed as one of the most fatal diseases, and no effective targeting treatment is clinically available. Although CD44-targeting hyaluronic acid (HA) has been utilized as targeting ligands in many studies, no facile ways have been developed through HA self-assembly at the nanoparticle surface. Herein, we reported N-isopropylacrylamide-grafted chitosan-based nanoparticles self-assembling with HA (HA-NPs) through electrostatic forces and loaded with curcumin (CUR). The HA-NPs displayed pH-responsive properties due to the chemical modification of chitosan, and the preparation process was optimized by central composite design–response surface methodology. HA anchorage confers the vehicle with tumor-targeting capability. HA-NPs displayed more robust effects of inhibiting TNBC primary tumor growth than free CUR and a plain counterpart but without increased systemic cytotoxicity. In addition, in vivo pharmacokinetic studies showed that HA-NPs significantly increased the in vivo residence time of free CUR and improved the bioavailability of CUR. These findings suggested that chitosan-based HA-NPs may provide a feasible and unique strategy to achieve CD44 targeting and enhance its efficacy in vivo for the treatment of advanced TNBC.

Keywords